Currently approved and newer drugs in trials for thrombotic microangiopathies
| Name of the drug . | Target . | Route . | ClinicalTrials.gov . |
|---|---|---|---|
| Eculizumab | Anti-C5 | SC | FDA approved; NCT03518203 (HSCT-TMA) |
| Ravulizumab | Anti-C5 | SC | FDA approved; NCT04543591 (adult HSCT-TMA), NCT04557735 (pediatric HSCT-TMA), NCT04570397 (COVID-19) |
| Crovalimab | Anti-C5 | SC | NCT04861259 (adult aHUS), NCT04958265 (pediatric aHUS) |
| Nomacopan | Anti-C5 and leukotriene B4 | SC | NCT04784455 (transplant-associated TMA) |
| Iptacopan | Anti-factor B | Oral | NCT04889430 (adult aHUS) |
| Pegcetacoplan | Anti-C3 | SC | NCT05148299 (HSCT-TMA) |
| Narsoplimab | MASP 2 inhibitor | IV | NCT05855083 (pediatric HSCT-TMA) |
| Name of the drug . | Target . | Route . | ClinicalTrials.gov . |
|---|---|---|---|
| Eculizumab | Anti-C5 | SC | FDA approved; NCT03518203 (HSCT-TMA) |
| Ravulizumab | Anti-C5 | SC | FDA approved; NCT04543591 (adult HSCT-TMA), NCT04557735 (pediatric HSCT-TMA), NCT04570397 (COVID-19) |
| Crovalimab | Anti-C5 | SC | NCT04861259 (adult aHUS), NCT04958265 (pediatric aHUS) |
| Nomacopan | Anti-C5 and leukotriene B4 | SC | NCT04784455 (transplant-associated TMA) |
| Iptacopan | Anti-factor B | Oral | NCT04889430 (adult aHUS) |
| Pegcetacoplan | Anti-C3 | SC | NCT05148299 (HSCT-TMA) |
| Narsoplimab | MASP 2 inhibitor | IV | NCT05855083 (pediatric HSCT-TMA) |